Evidence map›Paper›PMID 41484135›Full record

ArticleNature communications2026

Neutralizing human monoclonal antibodies to poliovirus map to the receptor binding site.

Benjamin T Waddey, Andrew J Charnesky, Julia E Faust, Nadia M DiNunno, Rama Devudu Puligedda, Sung Hyun Cho, Carol M Bator, Steven D Dong, Kutub Mahmood, Konstantin M Chumakov and 2 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Benjamin T WaddeyCollege of Biological Sciences, University of Minnesota, Twin Cities, St. Paul, MN, USA.
Andrew J CharneskyEberly College of Science, The Pennsylvania State University, State College, Hershey, PA, USA.
Julia E FaustEberly College of Science, The Pennsylvania State University, State College, Hershey, PA, USA.ORCID http://orcid.org/0009-0005-6326-8818
Nadia M DiNunnoCollege of Medicine, The Pennsylvania State University, Hershey, PA, USA.
Rama Devudu PuligeddaLankenau Institute for Medical Research, Wynnewood, PA, USA.
Sung Hyun ChoThe Huck Institutes of Life Science, The Pennsylvania State University, State College, Pennsylvania, PA, USA.ORCID http://orcid.org/0000-0002-8191-7181
Carol M BatorThe Hormel Institute, University of Minnesota, Austin, MN, USA.
Steven D DongCenter for Vaccine Innovation and Access, PATH, Seattle, WA, USA.
Kutub MahmoodCenter for Vaccine Innovation and Access, PATH, Seattle, WA, USA.
Konstantin M ChumakovDepartment of Microbiology, Immunology, and Tropical Diseases, George Washington University, Washington, DC, USA.
Scott K DessainLankenau Institute for Medical Research, Wynnewood, PA, USA.
Susan L HafensteinCollege of Biological Sciences, University of Minnesota, Twin Cities, St. Paul, MN, USA. hafen@umn.edu.ORCID http://orcid.org/0000-0003-2609-4036

Funding

Bill and Melinda Gates Foundation (Bill & Melinda Gates Foundation) INV 010160Gates Foundation INV-010160U.S. Department of Health & Human Services | NIH | NIH Office of the Director (OD) RO1 AI10721-01U.S. Department of Health & Human Services | NIH | NIH Office of the Director (OD) S1000D026922-01
6 · The paper itself

Abstract

Poliovirus remains a serious threat to human health. Complete eradication of wild-type poliovirus has not yet succeeded, making the development of successful antivirals critical. Microneutralization assays against all three poliovirus serotypes identified a panel of human monoclonal IgGs, which are either serotype-specific or cross-neutralizing. Here, through cryoEM single particle analysis, we solved high resolution structures of four distinct poliovirus-FAb complexes. These antibodies bind to capsids at the circular depression (canyon) surrounding the icosahedral five-fold symmetry axis, which is also the binding site of the poliovirus receptor (PVR). Analysis of these structures confirms overlap of FAb contacts on the viral capsid with those of PVR. For three of the FAbs, the capsid residues are identified that dictate serotype-specific recognition. Contacts for the cross-neutralizing mAb 10D2 are located deep in the capsid canyon. These structural analyses indicate that antibody competition with the receptor likely leads to neutralization of virus particles and inhibition of poliovirus entry into host cells. Thus, the human IgGs studied here may facilitate development of therapeutics for the ongoing efforts in global eradication of poliovirus.

Indexed as

Antibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralPoliovirusReceptors, VirusBinding SitesCapsidCapsid ProteinsCryoelectron MicroscopyHumansImmunoglobulin Fab FragmentsModels, MolecularAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralCapsid ProteinsImmunoglobulin Fab Fragmentspoliovirus receptorReceptors, Virus

Identifiers

PMID41484135
PMCPMC12891506

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.